Debt-to-equity of Fusion Pharmaceuticals Inc. from 30 Sep 2021 to 31 Mar 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Fusion Pharmaceuticals Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2021 to 31 Mar 2024.
  • Fusion Pharmaceuticals Inc. Debt-to-equity for the quarter ending 31 Mar 2024 was 32%, a 16% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Fusion Pharmaceuticals Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q1 2024 32% +4.4% +16% 31 Mar 2024
Q4 2023 32% +11% +49% 31 Dec 2023
Q3 2023 34% +18% +121% 30 Sep 2023
Q2 2023 32% +22% +214% 30 Jun 2023
Q1 2023 28% +19% +225% 31 Mar 2023
Q4 2022 21% +14% +174% 31 Dec 2022
Q3 2022 15% +8.3% +120% 30 Sep 2022
Q2 2022 10% 30 Jun 2022
Q1 2022 8.5% 31 Mar 2022
Q4 2021 7.8% 31 Dec 2021
Q3 2021 6.9% 30 Sep 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.